UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY

IN RE:)) 19-MD-2875(RBK-J	
)	Camden, NJ	
VALSARTAN NDMA PRODUCTS)	June 12, 2019	
LIABILITY LITIGATION)	3:04 p.m.	

TRANSCRIPT OF TELEPHONIC STATUS CONFERENCE
BEFORE THE HONORABLE JOEL SCHNEIDER
UNITED STATES MAGISTRATE JUDGE

APPEARANCES:

For the Plaintiffs:

ADAM M. SLATER, ESQUIRE MAZIE, SLATER, KATZ & FREEMAN, LLC 103 Eisenhower Parkway 2nd Floor Roseland, NJ 07068

RUBEN HONIK, ESQUIRE DAVID J. STANOCH, ESQ. GOLOMB & HONIK, PC 1835 Market Street Suite 2900 Philadelphia, PA 19103

DANIEL NIGH, ESQUIRE LEVIN PAPANTONIO 316 South Baylen Street Pensacola, FL 32502

CONLEE WHITELEY, ESQ.
KENNER & WHITELEY
701 Camp Street
New Orleans, LA 70130

BEHRAM V. PAREKH, ESQ. KIRTLAND & PACKARD, LLP 1638 Pacific Coast Hwy. Redondo Beach, CA 90277 For the Plaintiffs: MIKAL C. WATTS, ESQ.

WATTS GUERA, LLP

4 Dominion Drive, Bldg. 3

Suite 100

San Antonio, TX 78257

For the Defendants: SETH A. GOLDBERG, ESQUIRE

JESSICA A. PRISELAC, ESQUIRE

2

ALAN KLEIN, ESQUIRE DUANE MORRIS, LLP 30 South 17th Street Philadelphia, PA 19103

LORI G. COHEN, ESQUIRE

VICTORIA D. LOCKARD, ESQUIRE

GREENBERG TRAURIG, LLP 3333 Piedmont Road NE

Suite 2500

Atlanta, GA 30305

CLEM C. TRISCHLER, ESQUIRE PIETRAGALLO GORDON ALFANO BOSICK & RASPANTI, LLP

One Oxford Centre

38th Floor

Pittsburgh, PA 15219

RICHARD W. SMITH, ESQUIRE

WILEY REIN, LLP 1776 K Street NW Washington, DC 20006

BRIAN RUBENSTEIN, ESQUIRE

GREENBERG TRAURIG 1717 Arch Street

Suite 400

Philadelphia, PA 19103

Audio Operator: TARYN FRANCHETTI

Transcribed by: DIANA DOMAN TRANSCRIBING, LLC

P.O. Box 129

Gibbsboro, NJ 08026 Office: (856) 435-7172 Fax: (856) 435-7124

Email: dianadoman@comcast.net

Proceedings recorded by electronic sound recording; transcript produced by transcription service.

Case 1 19-md-02875-RMB-SAK Document 124 Filed 06/18/19 Page 3 of 29 PageID: 1547

3

1	<u>I N D E X</u>		
2			
3	COLLOQUY RE:	PAGE	
4	Confidentiality order	6	
5	Core discovery	9	
6	Master complaints	16	
7	Short form complaints	16	
8	Insurance information	16	
9	Streamlined service protocol	21	
10	Plaintiff fact sheets	21	
11	Stipulation for dismissal	23	
12	Document repositories	23	
13			
14			
15			
16			
17			
18			
19			
20			
21			
22			
23			
24			

4

(The following was heard via telephone conference at 1 2 3:04 p.m.) THE COURT: Good afternoon, Counsel. Judge 3 Schneider here in the matter of In Re: Valsartan MDL. We're 4 5 on the docket -- excuse me, we're on the record. Docket Number 19-2875. And thank you very much for your indulgence 6 7 in moving the conference call up to 3 o'clock from 4 o'clock. I'm very grateful. 8 Could we have the names of counsel on the phone 9 starting with plaintiff's counsel? 10 11 MR. SLATER: Good morning, Your Honor. Adam Slater 12 for the plaintiffs. MR. HONIK: Ruben Honik for plaintiff. 13 MR. NIGH: Daniel Nigh for plaintiff. 14 15 THE COURT: Okay, defense counsel? 16 MR. GOLDBERG: Seth Goldberg on behalf of the Princeton defendants and the joint defense group. 17 MS. COHEN: Good afternoon, Judge. This is Lori 18 19 Cohen on behalf of the Teva defendants and the joint group as well. 20 MR. TRISCHLER: Clem Trischler, Your Honor. Good 21 22 afternoon. Representing Mylan Pharmaceuticals and the joint

Is that all?

This is

MR. PAREKH: Good afternoon, Your Honor.

defense group.

THE COURT: Okay.

23

24

25

Behram Parekh on behalf of the plaintiff. (inaudible)

THE COURT: Anybody else? Okay, great. Counsel, thank you for your agendas. Like I said when we spoke, I'm perfectly fine for these calls with separate submissions so long as it's the same issues everybody addresses in the same order. So I have absolutely no problem with what you submitted. It was a terrific update on the issues.

I'm on the bench. My law clerk's getting my -- my copies of the letters, so I don't have it in front of me now.

Let's just go down each of the topics one by one. I've read them. I know what the issues are. And we'll see what we have to discuss.

So what's issue number -- what's topic number one?

UNIDENTIFIED COUNSEL: The confidentiality order,

Your Honor.

THE COURT: Okay. I really want to get that entered because I just don't want someone to argue that they don't have to produce documents because the order isn't entered yet. Where are we on that?

UNIDENTIFIED COUNSEL: Your Honor, the confidentiality order was revised by the defense and sent over to us late Monday. Honestly, between then and now I haven't had a chance to go through it in detail, but I would expect that no later than Monday I can get back to the defense and tell them if there's any remaining issues.

Colloquy

MS. COHEN: And Judge, good afternoon again. This is Lori Cohen. So we're actually waiting to get the transcripts, and I don't mean to follow up with any criticism, but we wanted to go that, you know, compared to the draft as well. So he did send us a plan. I think we were all hoping that we could have the draft to look at as well.

And Mr. Slater's timeline works for us. We may have some additional minor changes. But to your concern, I don't think anyone is going to hold back on producing anything, because I think you suggested at the last conference that anything produced be subject to the, you know, the same confidentiality order under the district anyway. So I think we can -- we won't need the lack of an executed signed confidentiality order. I think we would produce them subject to the confidentiality order that exists as you suggested. And hopefully we'll have this resolved by then anyway.

THE COURT: Okay. Terrific. Did -- did the parties order the transcript?

MS. COHEN: We did, Your Honor. And I think it was supposed to be done this week. Again, I know it was -- it was a long hearing. So again, I don't want to be a critic of --

THE COURT: No, no, no. They're very good. They're very good.

MS. COHEN: And we could -- yeah, we should have it. We were supposed to have -- I think the estimate was Monday,

and we didn't get it on Monday. So I think we want to have it to go through some -- there are a few additional items. We can wait and see if the plaintiffs agree with us, and then raise them with you. Or I can, you know, kind of highlight a few of them now. But I think we're very close.

THE COURT: Okay.

MS. COHEN: We just have -- you know, there are a few -- a few lingering issues, and maybe the transcript will help us, and maybe we can come back to you with one or two last points.

THE COURT: That's fine. I understand why you want to see the transcript. If you don't get it by tomorrow, we'll follow up with the transcription service. They're usually very, very good.

So you'll get the transcript. I agree, the production won't be held up. You can still rely on the district's order. And we'll put this on the agenda that it absolutely will be finalized by -- when is the next conference, June 26th?

MS. COHEN: Right.

THE COURT: Yeah. No problem. We'll finalize it June 26th.

MS. COHEN: Judge if we -- now if we have -- we can't reach agreement, and just to alert you we had four additional imperatives and some red lines that we thought

still needed to be worked out. So it's not a huge amount. I know it took some time at the last conference. If we still have a few issues, should we set a separate call with you to go over them, or present them to you in an email? What's the best avenue to get this finalized if we want to do it before the next conference?

THE COURT: You can just send me a letter with what the issues are and I'll rule on it. Or, it's only a week or two, you could put it in the joint agenda for the 6/26 and we'll decide it at the conference.

MS. COHEN: Okay.

THE COURT: What's ever easier.

MS. COHEN: I'm happy to get it, to highlight it even now, but since plaintiff they hadn't fully reviewed it yet, it might make more sense to let them do that, and then we can talk through it and then come back to you.

THE COURT: I agree. I think that makes much sense.

UNIDENTIFIED COUNSEL: Just one thing Judge, because Ms. Cohen was making -- had thrown together the idea of possibly talking before the conference. I had informed Your Honor that I will be, unless something changes, not at the next conference because I'm supposed to be out of the state on vacation, which I'm trying to change but having some trouble. If we have any discreet issue, then I think it would be helpful just to talk to them directly with Your Honor.

9

THE COURT: Let's do it. 1 2 UNIDENTIFIED COUNSEL: Rather than me having to explain it to someone else. Could we call, maybe, if that is 3 an issue? 4 5 THE COURT: No problem. Send me a email about -- or a quick call. Absolutely no problem. We'll find time to get 6 it finalized. 7 UNIDENTIFIED COUNSEL: Thank you, Judge. 8 THE COURT: Happy to --9 UNIDENTIFIED COUNSEL: It won't be an issue. 10 11 THE COURT: Right. We'll be happy to do that to get 12 it done. Core discovery. I've read Mr. Goldberg's letter. 13 have the letters in front of me now. It looks like, you know, 14 they'll be produced timely. We have the extension. There's 15 16 going to be the rolling production. And it looks like the 17 production's going to be pursuant to the ESA protocol. So do we have an issue, Mr. Slater? 18 19 MR. SLATER: No. If it's pursuant to the ESI protocol, that's fine. 20 THE COURT: What I'd like to do is I hope --21

MR. GOLDBERG: Your Honor -- Your Honor, this is

Seth Goldberg. I think we have to clarify what -- when we're
talking about producing under the ESI protocol. Because our
production as we envision it will not be under the ESI

22

23

24

25

Colloquy

protocol to the extent that that protocol requires certain categories of metadata be produced with the documents. We intend to produce these documents, this batch of documents of core discovery, as Bates stamped PDFs with a subset of categories of metadata. The ESI protocol, which is a much more complex -- requires a much more complex set of metadata and production requirements.

Our understanding as set forth in the core discovery order and how we've approached core discovery was, for expediency's sake, it was important to get the documents which are not in traditional ESI emails from (inaudible)in an ESI format so that we can get them over to plaintiffs quickly. And that's how we've approached it. We think that that's a sufficient producia for what the Court has envisioned with respect to core discovery.

MR. SLATER: Your Honor, it's Adam Slater. I'm going to hand it off to Mr. Parekh in one second. Just -- and the other issue with that, as we expressed in our letter, because we didn't believe that the fact that it's core discovery should limit our avail -- our ability to have the full information.

Now, what we said in our letter is if they want to produce it in that format now, but then in a short time produce it compliant with the ESI protocol, we can live with that if it's a timing issue. But, and I'll let Mr. Parekh

Colloquy

talk a little more about the technicalities right now on some of the types of documents.

THE COURT: Let me -- can I just weigh in on this for a second? Given that this is the quote-unquote "core discovery," and what we envisioned by that is the unquestionably relevant and some of the most important documents in the case, it would seem logical that eventually plaintiffs would get the same sort of metadata that they are going to get with the other documents in the case.

I have no problem, zero problem, if these documents are produced to plaintiff so that they could get the ball rolling. And subsequently down the road we'll get supplements from defendants as to the requested data.

But what I'd like to do is this. I'd like to handle all issues regarding the core discovery at one time. Just like the insurance information, I would be very pleasantly surprised if plaintiff is satisfied with everything they receive, that it's in full 100 percent compliance with the Court's order. Something tells me that won't happen, although I would love for that to happen.

So what I think is the prudent way is, let's wait until July whatever when the production is supposed to be complete, and then plaintiff can raise every issue at once about the production, including it wants X, Y, Z metadata for these documents, and we'll just deal with the issues at one

time collectively rather than dealing with it piecemeal.

I don't see any prejudice to the plaintiff. They're going to get the documents. They could start reviewing them.

And if the Court rules that the metadata has to be supplemented, you'll get it in due course.

Any problem if we proceed that way, plaintiffs?

MR. SLATER: No problem at all, Judge. That's very reasonable.

THE COURT: Okay. So I don't know if the defendants are taking the position they don't think they have to produce the missing metadata for the core discovery. But it doesn't matter. We'll deal with that issue at one time, Mr. Goldberg.

MR. GOLDBERG: Yeah, Your Honor -- Your Honor, I just would, you know, just sort of highlight one issue that is -- I guess two issues. One is when we saw, you know, Mr. Slater's letter, I think the defendants independently looked at their productions. And you know, certainly producing -- I don't think the defendants are opposed to producing that kind of metadata.

I think one of the questions is if we go through now with the full production of the information, and then are required to produce -- produce it pursuant to the ESI protocol if we're under the ESI protocol, there is going to be A) a significant expense that's, you know, sort of something that we're going to have to address. And there will be a lag time

Colloquy

THE COURT: So why don't you just produce it?

for that. And just as long as that -- those two issues are addressed by the Court, I think that we're -- we're not at this point formally opposed to producing the metadata.

MR. GOLDBERG: We can, you know, (inaudible). We've taken this approach to really -- to satisfy the Court's requirement that it be done quickly. And you know, had -- had there not been this need to have it done quickly, we would have done one production of the core discovery subject to the ESI protocol, but somewhere down the line. And so that shifts

-- there's a tension here because, you know, plaintiffs may

just say hey, reproduce it.

But, you know, there's a real cost to that. You're running a -- you're running thousands of documents with various kinds of files through a vendor. And so it is -- there's a very real cost to that that we should just be cognizant of. And while we can produce this stuff now, that will be an issue that we deal with later. Or do, you know, the Court say let's put off the production of core discovery. We're not suggesting that, but we are suggesting that there is some sort of burden that's being put on the defendants by having to reproduce information.

It's not clear to us why every category of metadata would be required with respect to this kind of information.

And maybe a better approach to address this cost issue, and

Colloquy

maybe we can deal with it in July, is to say plaintiffs demonstrate why you need more metadata. Because we shouldn't have a compromised position where we're producing certain kinds of documents in the files, i.e. spreadsheets, right? Because that's the kind of information you need to manipulate.

But the way we intend to produce the PDFs should reflect the format (inaudible). So what you're -- what essentially may be happening here is to satisfy a hypertechnical concern about (inaudible) causing a significant burden on the defendants to reproduce a large volume of information.

THE COURT: Mr. Goldberg, here's what I have to say to what you just said. If the defendants want to avoid the expense of doing something twice, then when you make your production by July, produce all the requested metadata in the ESI protocol. If you don't want to do that, we'll deal with the issue separately when we deal with all core discovery issues. And it's very possible this Court may order the defendants to produce the supplemental metadata in the ESI protocol.

So you know, if the defendants are worried about the cost, then just produce it the first time. I don't have a problem with that. I'm not going to delay the production dates any longer.

MR. GOLDBERG: Right. I think the question is, you

Colloquy

know, is there -- is that -- is it -- and we'll certainly look at that, Your Honor, is it feasible for us to do something like that in the next month with respect to this information. We do have the production on June 17. And so, you know, I think it's unlikely that we would be able to produce, let's say, the ANDA files which we're all planning to produce next week along with the metadata for those ANDA files, The metadata that would be required under the ESI protocol.

THE COURT: I'm not -- I agree with you. I'm not sure you do need the metadata for the ANDA files. I'm not sure. If there's a legitimate --

MR. GOLDBERG: And that's where we would say -- we would say well, maybe they should demonstrate why they need that kind of metadata for those kinds of files if we've already produced the PDFs. They can see how they were produced to the FDA. Maybe that should be sufficient with respect to these kinds of documents, ANDA files and drug master files.

THE COURT: I think we're going in --

MR. GOLDBERG: This is not an email.

THE COURT: I think we're going in circles. So if that's the position the defendants want to take, like I said, it's perfectly fine with the Court. Don't produce it, and after July all these issues will be dealt with at one time. All of your objections to producing metadata pursuant to the

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

Colloquy

16

ESI protocol, and all of plaintiff's likely objections to the completeness of the production, which I hope doesn't happen but we live in the real world. It's going to happen. We'll deal with them all at one time. Okay? So let's go to the next issue, master complaints. Plaintiffs are going to file them on time, right? And then we'll -- the responses are stayed. And then the issues will be joined, I think, right plaintiff? Are we going to see any surprises do you think, plaintiffs? MR. SLATER: I hope not, Your Honor. THE COURT: Okay. UNIDENTIFIED COUNSEL: It'll surprise us. THE COURT: Short form complaints. Can we get that finalized by the 26th? MR. NIGH: Your Honor, this is Daniel Nigh. We sent our proposal for the short form complaints to defendants. don't believe we've received any response back from them. THE COURT: Yeah. I think, if I remember right, they said they're going to respond by June 14th. So we'll put that on the agenda for June 26th. MR. NIGH: Fine. Insurance information. Can I hear from THE COURT: the defendants on this first, given plaintiff's letter? MR. GOLDBERG: Sure, Your Honor. This is Seth

Goldberg. You know, it's our understanding that all of the

Colloquy

defendants are to produce insurance policies that had insurance policies have produced them. I understand Teva, you know, provided something different. And that's something that Teva will work out with plaintiffs.

And as we indicated in our letter, to the extent there are reservation of rights letters, you know, we're -- and to make that determination whether they've been issued. And you know, would supplement production with those to the extent there are any.

THE COURT: Well, I have a letter from plaintiffs, maybe it was updated, that says there was no disclosure by CHP, Torrid (phonetic), Hetero. What do we do with those?

MR. GOLDBERG: So I think -- yeah, I think the -- I think the issue is that, you know, and I think what plaintiffs are viewing as no disclosure, the result is because there is no policy. And I think what -- the way this was approached was some of the parties simply just sent an email with their policy to plaintiffs, not a formal Rule 26 disclosure with a caption and a response, attaching the policy. We just provided the policy.

So you know, for instance, in the case of CHP, or the case of Torrid, there isn't a policy. With respect to Hetero, it is my understanding that Hetero USA, which is the only Hetero entity in the -- in the MDL that's been served and is being represented in the MDL, does not have a policy. I'm

Colloquy

sorry, was not subject to the core discovery order, because it is not a API manufacturer or finished dose manufacturer. It is -- it views itself to be the FDA liaison only.

THE COURT: Okay. So plaintiffs, are you satisfied with Mr. Goldberg's representation that CHP and Torrid have no insurance to disclose?

UNIDENTIFIED COUNSEL: Yeah. I mean, if they have nothing, they have nothing. I was going to suggest, listening to Mr. Goldberg speak, that it might make sense, so that we don't have ambiguity and everybody knows exactly where we stand, if the defense could send us -- it even can be done by a letter, it's fine -- listing each of the parties that were subject to the order and just confirming what they have produced. Or if there's no insurance, to say there's no insurance, so that nobody is having to keep together a bunch of emails so everybody has it in one place.

And I think, you know, we added also that we thought that it would be a good idea to speak to the defense just so we can talk through the insurance issues and make sure that nothing's being missed. For example, it looks like these are claims made policies that we've seen, and we had some question about whether they were current stage policies, whether there were any tails on other policies, just to make sure that every stone's been unturned, you know, overturned, and just to make sure nobody misses anything. We just want to be reasonable

Colloquy

that, you know, one document that says this is everything, and then talk to the defense and make sure that, you know, nobody's missed anything along the way.

MS. COHEN: And Judge, this is Lori Cohen. I can just comment here on behalf of Teva because there was a reference in the letter to you under side B that we said there was no need to disclose, which isn't accurate. We actually did a pleading saying that we were disclosing our insurance information consistent with the order and pursuant to Federal Rules of Procedure 26A:1a(4), just like the order said.

Our response is saying more than you need to hear, Judge. But since we're one of the main defendants, we said that Teva is self-insured beyond any award anticipated in the case at this time. And so we actually disclosed in a pleading to make it very clear that we were stating this on behalf of our clients and ourselves, and we do think it's compliant.

And basically we said that because the Rule 26:A that we referenced requires disclosure of any insurance which may be liable to satisfy all or part of the possible judgment. We think we have disclosed that, but we're happy to talk further with Mr. Slater and the plaintiff team. There were no reservation rights letters. But I think we do disagree with the statement that we said there was no need to disclose it, because we actually disclosed in these pleadings.

UNIDENTIFIED COUNSEL: I think we're explaining a

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

Colloquy

20

semantic issue here. If I understand Ms. Cohen in her disclosure, which I think we understood very well, they were saying we have excess policies that your case isn't worth enough to get close to those excess policies, so you don't need to know what they are. That's my street interpretation of it. So I think if there's an insurance policy that's in existence, needs to be disclosed.

THE COURT: Well, let me -- let me -- if I had to do it over again, I would make my order more specific to avoid these sorts of problems. I think all the response of defendants' disclosures should be in writing. The failure to submit something in writing does not -- should not necessarily be deemed to mean they have no insurance. Plaintiff doesn't know if they are just ignoring the direction to advise them of the insurance. Excess policies have to be identified, and reservation of rights, and declaration letters have to be That's what I intended to mean by my order. produced. Granted it wasn't as clear as it could be, but I'm going to clarify the order. And to the extent the disclosure wasn't done in accordance with the old order, I'll just order it be supplemented.

Rather than putting burden on defendants, Mr. Slater, to prepare a list of responsive defendants and what they said, I think the burden should be on plaintiffs in that regard. I think the plaintiffs should put together what

disclosures they have. And if there's something missing, let's get it identified and let's get it produced, okay?

MR. SLATER: We will, Judge. If I understand you want us to send them a letter saying this is what our understanding is as of what's been produced. And to the extent there's anything that either -- if there's a party that has no insurance, please disclose that so we (inaudible)

THE COURT: Yes.

MR. SLATER: If there's anything else, please let us know if we missed it.

THE COURT: And you should also -- you should also identify who the plaintiffs think the responsive defendants are so the plaintiffs and defendants are on the same page with that.

MR. SLATER: Will do.

THE COURT: Okay. So my order is going to say the response has to be in writing. Excess policies have to be identified. Reservation of rights and declaration letters have to be produced. There's a continuing obligation, obviously, to supplement that disclosure. And we'll give the defendants more time to do that in the event they haven't done it to date.

Okay. Number six, streamlined service protocol. You can submit it to the Court. We'll sign it right away. That's perfect.

Plaintiff fact sheets. Ms. Cohen, I know this was important to you, so I'd like to stay on top of it.

MS. COHEN: Yes. Yes, exactly, Your Honor. And we are -- we've been working amongst the defense group on that. And we will have a first draft of the plaintiffs' fact sheet, the personal injury plaintiff, circulated by no later -- no later than this Friday, the 14th.

THE COURT: Great.

MR. SLATER: Fine.

MS. COHEN: And then we're working on the other two, that is (unidentified) for the third-party payer and consumer class representative. And we intend to get that circulated hopefully by next Wednesday the 19th. So we'll have them both in the plaintiffs' hands. Hopefully we can hear back from them quickly so we can discuss them with you on the 26th.

THE COURT: Fantastic. I guess the plaintiffs should work on the defendants' fact sheet, right?

MR. SLATER: We certainly can -- we can start to do that and speak to the defendants. I think it's going to depend on how things are structured in discovery. You know, I think that in terms of general discovery we probably don't need a fact sheet. I would think those will become more relevant when we get to a bellwether process, but we can certainly start to do that as well.

THE COURT: Okay. Well that ball is in the

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

Colloquy

23

plaintiffs' court. If you want the defendants to prepare fact sheets, the different categories of defendants, then the ball's in plaintiffs' court to get a first draft to the defendants. MR. SLATER: Will do. THE COURT: ESI protocol, fantastic. Just send it to the Court. We'll take care of entering it. The stipulation for dismissal, I think the defendants going to get back to you by the end of this week. That's great. Hopefully we can discuss it on the 26th if we have to. Document repositories. Sounds like -- I don't remember. Were we talking about a joint repository, or separate repositories for plaintiffs and defendants? MR. GOLDBERG: Separate repositories, Your Honor. THE COURT: Okay. So defendants are working on their issue? MR. GOLDBERG: Yeah, defendants have identified and we're working on creating a repository. THE COURT: Fantastic. Coordination of state cases. It looks like -- I don't know if Judge Kugler has spoken to the state judges yet, but if he hasn't he will. It's great

MR. GOLDBERG: Yeah, Your Honor. Just giving you

that so far they -- looks like they seem to be on board with

coordination. We'll have to see how that develops.

two cases, <u>Runo</u> and <u>Orlowsky</u>. We entered the stipulation in both cases that was ordered in <u>Runo</u> and hasn't been answered by the Court, and I'll ask to get that sent, that coordinates defendants' response to the complaint in those cases to any sort of responses, put it in the MDL. But it doesn't coordinate those cases for purposes of discovery.

THE COURT: Oh. Okay.

MR. GOLDBERG: So we would ask if Your Honor or Judge Kugler could reach out to those judges. The court in Orlowsky has set a scheduling conference for July 18. And we would think if Judge Kugler could reach out to that judge in advance of that, that may -- that may help things.

But again, Victor Orlando, who was in Court last -- a few weeks ago, did a brief to coordinate those actions. So there shouldn't be a problem, but it may be helpful if Judge Kugler reaches out to the judges in the New Jersey Court actions.

THE COURT: I agree with you, and we'll take care of that. It looks like the Chicago case, is that active?

MR. SLATER: That is active, and there's been motions crafted. We filed -- the only defendant in that action is Walgreen's. And pursuant to their indemnity agreement that our client, that SALCO (phonetic) has, we have attempted to join that action. There's been motion practice with respect to that. And no discovery issues in the near --

in the near term in that case. So it may be better with respect to that case, since we have a little time to see how the motions play out. But we would envision trying to get that matter coordinated to the extent it is still in existence as this case proceeds.

THE COURT: Just to double check, do you think it would be helpful if this Court reaches out -- Judge Kugler or I reaches out to the judge in Chicago to just touch base with them about what's happening here?

MR. SLATER: I do, because that is, you know, sort of the basis of our join in is to get the action in for Federal Court so that we could get it put into the MDL.

THE COURT: Okay. We'll -- we'll take care of it.

MR. SLATER: Okay.

THE COURT: We'll take care of it. Okay, Losartan, the other two Sartans, plaintiffs do you have any idea when you're going to move before the MDL? And defendants, plaintiffs want to know if you'll oppose the inclusion.

MR. HONIK: Your Honor, Ruben Honik. We do intend to file. I apologize I'm not in my office, and I from memory cannot recall if the panel is meeting in July and not again until September. I believe that's the case. And if so, we'll be targeting the September hearing.

There is, as everyone I believe knows already, a Losartan and Irbesartan class case. There is to my knowledge

Colloquy

at least one stand alone Losartan bodily injury case. I'm informed there will be more.

And candidly, regardless of how large the pool of Losartan and Irbesartan cases are, the petition I think should be favorably viewed on JPML inasmuch as we're not asking them to create a Sartan MDL. We already have it. We just wish to expand it to include other recalled products. And we're confident that the Court will view it that way, or the panel will view it that way.

And yes, we very much would like to know if this is a petition that can be joined in with the defendants. We can't figure any reason for these cases to go anywhere but to Camden.

MR. GOLDBERG: Your Honor, this is Seth Goldberg. I think -- I think most of the defendants would agree with that. We haven't heard from all of them, and there may be, you know, there may be some defendants who talk about 43 parties that have, you know, a different insurance. But there may be some joinder by some of the defendants, but not all of the defendants, which never presumably seem persuasive --

So I would just encourage Ruben, you know, to let's connect on that before you end up filing a petition.

THE COURT: Yeah.

MR. HONIK: Absolutely we'll do that. And I'm heartened by your answer, Seth. Thank you.

Colloquy

THE COURT: Mr. Honik, just a suggestion. I understand the practical difficulty the defendants have trying to rope 43 defendants or so into one position. But in the event they can't get that unanimity, it would seem to me that it would be persuasive to the panel if you could just speak on behalf of, you know, what we consider the sort of targets or the main defendants in this case, the API people we've been talking about. I think their inclination would carry more weight than a peripheral defendant who may object.

MR. HONIK: Absolutely. Absolutely.

THE COURT: Okay. We -- we finished the written agenda. I think we're making progress. Are there any other issues that the parties think it would be helpful to address now?

MR. SLATER: Nothing for the plaintiffs.

MR. GOLDBERG: Nothing from the defendants, Your Honor.

THE COURT: I spoke to Judge Kugler. He's going to be at the next conference, obviously. I think what we'd like to do if the schedule permits, and the timing permits, is we'll have the discovery conference in the morning and then just roll right into Judge Kugler's conference if that's okay with you. And I'm going to suggest to Judge Kugler that just like we sat down in the jury room after last conference and talked informally, that we do the same thing for a few minutes

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

Colloquy

28

on the 26th, and some of the questions that I couldn't answer, the big picture, case management type issues about bellwethers, and trials, and <u>Daubert</u> and all that, you can get input from Judge Kugler on that, which I think would be helpful as we move forward. UNIDENTIFIED COUNSEL: Great. THE COURT: So I'm going to ask Judge Kugler for his indulgence to do that. And I think it would be helpful to move the -- move the case along. All right? Thank you everybody. Again, I appreciate your indulgence moving up the time of the call. We'll see you on the 26th. If any issues -- we talked about the DCO. Be happy to set up a phone call on short notice to address any issue you want on the DCO or any other issue anybody wants to address. Thank you very much. Have a good day, Counsel. We're adjourned. (Proceedings concluded at 3:44)

CERTIFICATION

I, Sue Wynne, court approved transcriber, certify that the foregoing is a correct transcript from the official digital audio recording of the proceedings in the above-entitled matter to the best of my ability.

/s/ Patricia A. Hallman

PATRICIA A. HALLMAN

DIANA DOMAN TRANSCRIBING, LLC